- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07626411
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation (ROXI-EVEREST)
A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-EVEREST)
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.
The aim of the study is to see how safe and effective REGN7508 is in preventing stroke and/or systemic embolism in participants with atrial fibrillation and how it compares against participants that will receive apixaban in this study.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Clinical Trials Administrator
- Telefonnummer: 844-734-6643
- E-mail: clinicaltrials@regeneron.com
Studiesteder
-
-
-
Longueuil, Canada, J4H4B9
- Rekruttering
- Viacar Recherches Cliniques inc.
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 5G4
- Rekruttering
- Premiere Clinical Trial Network
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1LOK3
- Rekruttering
- Diex Recherche Inc.
-
-
-
-
Alabama
-
Alexander City, Alabama, Forenede Stater, 35010
- Rekruttering
- Advanced Cardiovascular
-
Dothan, Alabama, Forenede Stater, 36305
- Rekruttering
- SEC Clinical Research
-
Fairhope, Alabama, Forenede Stater, 36532
- Rekruttering
- Eastern Shore Research Institute
-
-
Arizona
-
Glendale, Arizona, Forenede Stater, 85306
- Rekruttering
- West Valley Clinical Trials
-
Scottsdale, Arizona, Forenede Stater, 85260
- Rekruttering
- Scottsdale Clinical Trials
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72205
- Rekruttering
- Arkansas Cardiology P.A.
-
-
California
-
Covina, California, Forenede Stater, 91723
- Rekruttering
- Valley Clinical Trials, Inc
-
Fremont, California, Forenede Stater, 94538
- Rekruttering
- Mission Cardiovascular Research Institute
-
Huntington Beach, California, Forenede Stater, 92648
- Rekruttering
- National Institute of California Heart and Vein Specialists
-
Inglewood, California, Forenede Stater, 90301
- Rekruttering
- Alliance Clinical Los Angeles
-
La Jolla, California, Forenede Stater, 92037
- Rekruttering
- Profound Research LLC at San Diego Cardiovascular Associates
-
Newport Beach, California, Forenede Stater, 92663
- Rekruttering
- Radin Cardiovascular Medical Group
-
Northridge, California, Forenede Stater, 91325
- Rekruttering
- Valley Clinical Trials, LLC dba Flourish Research
-
Pasadena, California, Forenede Stater, 91105
- Rekruttering
- Southern California Heart Specialists
-
Santa Maria, California, Forenede Stater, 93454
- Rekruttering
- FOMAT - Comprehensive Cardiovascular Care
-
Ventura, California, Forenede Stater, 93003
- Rekruttering
- Cardiology Associates Medical Group
-
West Hills, California, Forenede Stater, 91307
- Rekruttering
- Interventional Cardiology Medical Group
-
-
Florida
-
Boca Raton, Florida, Forenede Stater, 33434
- Rekruttering
- Excel Medical Clinical Trials, dba Flourish Research
-
Cutler Bay, Florida, Forenede Stater, 33189
- Rekruttering
- Nouvelle Clinical Research LLC
-
Inverness, Florida, Forenede Stater, 34452
- Rekruttering
- Nature Coast Clinical Research - Inverness
-
Medley, Florida, Forenede Stater, 33166
- Rekruttering
- South Florida Research Organization LLC
-
New Smyrna Beach, Florida, Forenede Stater, 32168
- Rekruttering
- Healix Clinical Research
-
Pensacola, Florida, Forenede Stater, 32503
- Rekruttering
- Sec Clinical Research
-
Saint Augustine, Florida, Forenede Stater, 32086
- Rekruttering
- Flourish Research, St. Johns Center for Clinical Research
-
Sarasota, Florida, Forenede Stater, 34239
- Rekruttering
- Cardiovascular Center of Sarasota Foundation for Research and Education
-
Winter Park, Florida, Forenede Stater, 32789
- Rekruttering
- Clinical Site Partners, LLC DBA Flourish Research
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30342
- Rekruttering
- Atlanta Clinical Research Centers
-
Atlanta, Georgia, Forenede Stater, 30310
- Rekruttering
- Morehouse School Of Medicine
-
Johns Creek, Georgia, Forenede Stater, 30024
- Rekruttering
- NSC Research, Inc
-
-
Indiana
-
Hobart, Indiana, Forenede Stater, 46342
- Rekruttering
- Profound Research, Advanced Cardiovascular Care + Electrophysiology Clinic
-
Munster, Indiana, Forenede Stater, 46321
- Rekruttering
- Profound Research, Powers Health Medical Group - Electrophysiology
-
Munster, Indiana, Forenede Stater, 46321-4054
- Rekruttering
- Cardiovascular Research of Northwest Indiana, LLC
-
-
Louisiana
-
West Monroe, Louisiana, Forenede Stater, 71291
- Rekruttering
- Monroe Research, LLC
-
-
Maryland
-
Ft. Washington, Maryland, Forenede Stater, 20744
- Rekruttering
- Anderson Medical Research
-
-
Massachusetts
-
Foxborough, Massachusetts, Forenede Stater, 02035
- Rekruttering
- K2 Medical Research, Foxboro
-
-
Michigan
-
Bloomfield Hills, Michigan, Forenede Stater, 48304
- Rekruttering
- Profound Research, Cardiology and Vascular Associates (CAVA) - Bloomfield Hills
-
Farmington Hills, Michigan, Forenede Stater, 48334
- Rekruttering
- Profound Research, Millennium Cardiology
-
Flint, Michigan, Forenede Stater, 48503
- Rekruttering
- Flint Clinical Research
-
-
New York
-
Staten Island, New York, Forenede Stater, 10309
- Rekruttering
- Super Health Pharmacy
-
-
North Carolina
-
Concord, North Carolina, Forenede Stater, 28025
- Rekruttering
- Hawthorne Health, Moose Pharmacy of Concord
-
High Point, North Carolina, Forenede Stater, 27260
- Rekruttering
- Peters Medical Research
-
-
North Dakota
-
Fargo, North Dakota, Forenede Stater, 58104
- Rekruttering
- Lillestol Research LLC
-
-
Ohio
-
Marion, Ohio, Forenede Stater, 43302
- Rekruttering
- K&R Research LLC
-
Maumee, Ohio, Forenede Stater, 43537
- Rekruttering
- Advanced Medical Research
-
-
South Dakota
-
Rapid City, South Dakota, Forenede Stater, 57701
- Rekruttering
- Monument Health Clinical Research
-
-
Tennessee
-
Tullahoma, Tennessee, Forenede Stater, 37388
- Rekruttering
- Tennessee Center for Clinical Trials
-
-
Texas
-
Amarillo, Texas, Forenede Stater, 79106
- Rekruttering
- PharmaTex Research
-
Brownsville, Texas, Forenede Stater, 78520
- Rekruttering
- PanAmerican Clinical Research
-
Houston, Texas, Forenede Stater, 77061
- Rekruttering
- Synergy Groups Medical
-
Houston, Texas, Forenede Stater, 77094
- Rekruttering
- West Houston Area Clinical Trial Consultants, LLC
-
Missouri City, Texas, Forenede Stater, 77459
- Rekruttering
- Synergy Group Medical, LLC
-
Odessa, Texas, Forenede Stater, 79761
- Rekruttering
- Permian Research Foundation
-
Tyler, Texas, Forenede Stater, 75701
- Rekruttering
- Tyler Cardiovascular Consultants
-
-
Utah
-
Clinton, Utah, Forenede Stater, 84015
- Rekruttering
- Alpine Research TC
-
-
Virginia
-
Manassas, Virginia, Forenede Stater, 20109
- Rekruttering
- Carient Heart & Vascular
-
Vienna, Virginia, Forenede Stater, 22182
- Rekruttering
- Conquest Research
-
-
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 062-0003
- Rekruttering
- Hanaoka Seishu Memorial Hospital
-
-
Hyōgo
-
Kawanishi, Hyōgo, Japan, 666-0125
- Rekruttering
- The Veritas Hospital
-
-
Ibaraki
-
Higashiibaraki District, Ibaraki, Japan, 311-3193
- Rekruttering
- National Hospital Organization Mito Medical Center
-
Tsuchiura, Ibaraki, Japan, 300-8585
- Rekruttering
- National Hospital Organization Kasumigaura Medical Center
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 234-0054
- Rekruttering
- Saiseikai Yokohama-shi Nanbu Hospital
-
-
Kyoto
-
Kyoto, Kyoto, Japan, 607-8062
- Rekruttering
- Rakuwakai Otowa Hospital
-
-
Yokohama-shi
-
Kanagawa, Yokohama-shi, Japan, 247-0005
- Rekruttering
- JA Tsuchiura Kyodo General Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
-
Has AF or flutter (paroxysmal or persistent), not considered to be secondary to a reversible cause, and an indication for indefinite anticoagulation treatment as described in the protocol
-
Meets one of the following:
- CHA2DS2-VA [C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years (double points); D: Diabetes mellitus; S2: Stroke or TIA or Systemic embolism (double points); V: Vascular disease; A: Age 65-74 years] score ≥2 and Oral Anticoagulant (OAC) naïve OR
- CHA2DS2-VA score ≥3 OR
- CHA2DS2-VA score of 2 AND at least 1 enrichment criteria as described in the protocol
-
Must have an International Normalized Ratio (INR) <2.5 at the time of randomization if taking warfarin or another Vitamin K Antagonist (VKA)
Key Exclusion Criteria:
- Has a mechanical heart valve prosthesis (Note: transcatheter aortic valve replacement is not an exclusion)
- Has known moderate-to-severe mitral stenosis
- Has had a successful ablation therapy without documented recurrent AF or a participant after Left Atrial Appendage (LAA) occlusion/exclusion or plan for ablation or LAA occlusion/exclusion within the next 6 months starting from randomization
- Had an ischemic stroke within 2 days prior to randomization
- Has persistent, uncontrolled hypertension (per investigator's discretion)
- Has estimated Glomerular Filtration Rate (eGFR) <15 mL/min/1.73m2 within 30 days prior to randomization or is on dialysis or expected to be started on dialysis within the next 6 months starting from randomization
Note: Other protocol-defined Inclusion/ Exclusion criteria apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: REGN7508 + Placebo
|
Administered per the protocol Administered per the protocol
Andre navne:
|
|
Aktiv komparator: Apixaban + Placebo
|
Administered per the protocol Administered per the protocol |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type) or systemic embolism
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding or ISTH Clinically Relevant Non-Major (CRNM) bleeding
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or ISTH CRNM bleeding
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, or ISTH major bleeding
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or all-cause death
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of ISTH major bleeding
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of hemorrhagic stroke, intracerebral hemorrhage, or hemorrhagic transformation of an ischemic stroke
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Time to occurrence of fatal bleeding
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Number of ISTH major bleeding events
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Number of ISTH CRNM bleeding events
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Number of minor bleeding events
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Time to all-cause death
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: Approximately 39 months
|
Approximately 39 months
|
|
Severity of TEAEs
Tidsramme: Approximately 39 months
|
Approximately 39 months
|
|
Occurrence of Anti-Drug Antibodies (ADA) to REGN7508
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Magnitude of ADA to REGN7508
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- R7508-CVA-24114
- 2025-521617-97-00 (Ctis)
- 2025 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD-delingstidsramme
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD-delingsadgangskriterier
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .